Acrux Limited
ASX:ACR ISIN:AU000000ACR3
News
Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.
Last Friday, the Australian shares ended higher for the first time in a week. The benchmark S&P/ASX200 index gained 7.5 points, or 0.19 per cent, to 3,899.6 points, and the broader All Ordinaries index advanced 7 points, or 0.18 per cent, at 3894.4 points.
Acrux (ASX: ACR)(PNK:ARUXF) today announced that Evamist(tm), the first product utilising its unique skin spray drug delivery technology, has been launched by US licensee KV Pharmaceutical Company (NYSE: KVa/KVb) into one of the largest therapeutic categories in women's healthcare.
ACRUX LIMITED (ASX: ACR) - Market Briefing - Mr Igor Gonda, MD & CEO; Boardroomradio is pleased to announce that ACRUX LIMITED (ASX: ACR) has published an audio file. The following presentation "ACR -
48,014 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 13) (Last 30 Days: 62) (Since Published: 9882)